OBJECTIVE: The M.D. Anderson Symptom Inventory (MDASI) is a brief assessment of the severity and impact of cancer-related symptoms. The purpose of this study was the translation and validation of the questionnaire in Greek (G-MDASI). METHODS: The translation and validation of the assessment took place at a Pain Relief and Palliative Care Unit. The final validation sample included 150 cancer patients (61 males, 89 females, age range 31-88 years, mean age 63.32). The patients completed the questionnaires at the outpatient clinic. Assessing the validity and reliability constituted the actual validation of the G-MDASI. RESULTS: The item 'diarrhea' had a score of 0 in 139 patients and, thus was omitted from the 'core' list. Consequently, the core questionnaire consisted of 14 items. Factor analysis resulted in a 3-factor model, in both validation and cross-validation samples. The examination of the sensitivity of the MDASI revealed that there were differences between patients with poor-to-good performance status but no differences were found between patients in different treatment groups. CONCLUSIONS: The results showed that the G-MDASI is a reliable and valid measure in Greek cancer patients. It has proved to be a comprehensive symptom assessment tool.
OBJECTIVE: The M.D. Anderson Symptom Inventory (MDASI) is a brief assessment of the severity and impact of cancer-related symptoms. The purpose of this study was the translation and validation of the questionnaire in Greek (G-MDASI). METHODS: The translation and validation of the assessment took place at a Pain Relief and Palliative Care Unit. The final validation sample included 150 cancerpatients (61 males, 89 females, age range 31-88 years, mean age 63.32). The patients completed the questionnaires at the outpatient clinic. Assessing the validity and reliability constituted the actual validation of the G-MDASI. RESULTS: The item 'diarrhea' had a score of 0 in 139 patients and, thus was omitted from the 'core' list. Consequently, the core questionnaire consisted of 14 items. Factor analysis resulted in a 3-factor model, in both validation and cross-validation samples. The examination of the sensitivity of the MDASI revealed that there were differences between patients with poor-to-good performance status but no differences were found between patients in different treatment groups. CONCLUSIONS: The results showed that the G-MDASI is a reliable and valid measure in Greek cancerpatients. It has proved to be a comprehensive symptom assessment tool.
Authors: Tito R Mendoza; Xin Shelley Wang; Charles Lu; Guadalupe R Palos; Zhongxing Liao; Gary M Mobley; Shitij Kapoor; Charles S Cleeland Journal: Oncologist Date: 2011-02-01
Authors: G Brandon Gunn; Banu Atalar; Tito R Mendoza; Charles S Cleeland; Uğur Selek; Enis Özyar; David I Rosenthal Journal: Balkan Med J Date: 2016-05-01 Impact factor: 2.021
Authors: A Greco; E Orlandi; A Mirabile; S Takanen; C Fallai; N A Iacovelli; A Rimedio; E Russi; M Sala; D Monzani; D I Rosenthal; G B Gunn; P Steca; L Licitra; P Bossi Journal: Support Care Cancer Date: 2015-03-21 Impact factor: 3.603
Authors: Mary H Sailors; Diane C Bodurka; Ibrahima Gning; Lois M Ramondetta; Loretta A Williams; Tito R Mendoza; Sonika Agarwal; Charlotte C Sun; Charles S Cleeland Journal: Gynecol Oncol Date: 2013-05-15 Impact factor: 5.482